“Maintenance of Response With Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1): s23. https://doi.org/10.25251/skin.1.supp.22.